Hyperactivity Disorder Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hyperactivity Disorder stocks.

Hyperactivity Disorder Stocks Recent News

Date Stock Title
May 21 LLY Microcap Mangoceuticals doubles on plan to sell cheap oral GLP-1 weight loss meds
May 21 LLY Eli Lilly inks radiopharma deal worth up to $1.1B with Aktis
May 21 ALKS Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?
May 21 DRRX DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
May 21 LLY More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure
May 21 LLY Eli Lilly’s tirzepatide cleared for diabetes treatment in China
May 21 LLY Eli Lilly's diabetes drug tirzepatide gets approval in China
May 20 LLY Magnificent Seven? Just Two Members Clear This Bar
May 20 LLY The Zacks Analyst Blog Highlights Microsoft, Eli Lilly, Costco and Koss
May 20 LLY The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
May 19 LLY SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued?
May 19 LLY Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
May 17 LLY Top Research Reports for Microsoft, Eli Lilly & Costco
May 17 LLY 4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
May 17 LLY Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control
May 17 LLY Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
May 17 ALKS The Bottom Fishing Club: Alkermes Has Great Value And Safety
May 17 LLY Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
May 17 LLY Eli Lilly’s efsitora alfa shows promise in Phase III T2D trials
May 17 LLY Zacks Investment Ideas feature highlights: Apple, Eli Lilly and Crocs
Hyperactivity Disorder

Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It is characterized by difficulty paying attention, excessive activity, or difficulty controlling behavior which is not appropriate for a person's age. The symptoms appear before a person is twelve years old, are present for more than six months, and may cause problems in at least two settings (such as school, home, or recreational activities). In children, problems paying attention may result in poor school performance. Additionally there is an association with other mental disorders and substance misuse. Although it causes impairment, particularly in modern society, many people with ADHD can have sustained attention span for tasks they find interesting or rewarding (known as hyperfocus).Despite being the most commonly studied and diagnosed mental disorder in children and adolescents, the exact cause is unknown in the majority of cases. It affects about 5–7% of children when diagnosed via the DSM-IV criteria and 1–2% when diagnosed via the ICD-10 criteria. As of 2015 it is estimated to affect about 51.1 million people globally. Rates are similar between countries and depend mostly on how it is diagnosed. ADHD is diagnosed approximately two times more often in boys than in girls, although the disorder is often overlooked in girls because their symptoms differ from those of boys. About 30–50% of people diagnosed in childhood continue to have symptoms into adulthood and between 2–5% of adults have the condition. In adults inner restlessness rather than hyperactivity may occur. The condition can be difficult to tell apart from other conditions, as well as to distinguish from high levels of activity that are still within the range of normative behaviors.ADHD management recommendations vary by country and usually involve some combination of counseling, lifestyle changes, and medications. The British guideline only recommends medications as a first-line treatment in children who have severe symptoms and for medication to be considered in those with moderate symptoms who either refuse or fail to improve with counseling, though for adults medications are a first-line treatment. Canadian and American guidelines recommend that medications and behavioral therapy be used together as a first-line therapy, except in preschool-aged children. Stimulant medication therapy is not recommended as a first-line therapy in preschool-aged children in either guideline. Treatment with stimulants is effective for at least 14 months; however, their long term effectiveness is unclear. Adults often develop coping skills which make up for some or all of their impairments.The medical literature has described symptoms similar to those of ADHD since the 18th century. ADHD, its diagnosis, and its treatment have been considered controversial since the 1970s. The controversies have involved clinicians, teachers, policymakers, parents, and the media. Topics include ADHD's causes and the use of stimulant medications in its treatment. Most healthcare providers accept ADHD as a genuine disorder in children and adults, and the debate in the scientific community mainly centers on how it is diagnosed and treated. The condition was officially known as attention-deficit disorder (ADD) from 1980 to 1987, while before this it was known as hyperkinetic reaction of childhood.

Browse All Tags